Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 15;17(8):2710.
doi: 10.3390/ijerph17082710.

Increasing Incidence of Liposarcoma: A Population-Based Study of National Surveillance Databases, 2001-2016

Affiliations

Increasing Incidence of Liposarcoma: A Population-Based Study of National Surveillance Databases, 2001-2016

Suzanne Bock et al. Int J Environ Res Public Health. .

Abstract

Rare cancers, affecting 1 in 5 cancer patients, disproportionally contribute to cancer mortality. This research focuses on liposarcoma, an understudied rare cancer with unknown risk factors and limited treatment options. Liposarcoma incident cases were identified from the U.S. Surveillance, Epidemiology, and End Result (SEER) program and the combined SEER-National Program of Cancer Registries (CNPCR) between 2001-2016. Incidence rates (age-adjusted and age-specific), 5-year survival, and the time trends were determined using SEER*stat software. Three-dimensional visualization of age-time curves was conducted for males and females. SEER liposarcoma cases represented ~30% (n = 11,162) of the nationwide pool (N = 37,499). Both sources of data showed males accounting for ~60% of the cases; 82%-86% cases were identified among whites. Age-adjusted incidence was greater among males vs. females and whites vs. blacks, whereas survival did not differ by sex and race. The dedifferentiated (57.2%), pleomorphic (64.1%), and retroperitoneal (63.9%) tumors had the worse survival. Nationwide, liposarcoma rates increased by 19%, with the annual percent increase (APC) of 1.43% (95% confidence interval (CI): 1.12-1.74). The APC was greater for males vs. females (1.67% vs. 0.89%) and retroperitoneal vs. extremity tumors (1.94% vs. 0.58%). Thus, incidence increased faster in the high-risk subgroup (males), and for retroperitoneal tumors, the low-survival subtype. The SEER generally over-estimated the rates and time trends compared to nationwide data but under-estimated time trends for retroperitoneal tumors. The time trends suggest an interaction between genetic and non-genetic modifiable risk factors may play a role in the etiology of this malignancy. Differences between SEER and CNCPR findings emphasize the need for nationwide cancer surveillance.

Keywords: Liposarcoma; Surveillance, Epidemiology, and End Result (SEER) program; epidemiology; rare cancers.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1
Figure 1
Three-dimensional visualization of age-specific incidence rates of liposarcoma among males and females during the period of 2001–2016 from the combined Surveillance, Epidemiology, and End Result and National Program of Cancer Registries (CNCPR) data.

References

    1. Gatta G., Van Der Zwan J.M., Casali P., Siesling S., Tos A.P.D., Kunkler I., Otter R., Licitra L., Mallone S., Tavilla A., et al. Rare cancers are not so rare: The rare cancer burden in Europe. Eur. J. Cancer. 2011;47:2493–2511. doi: 10.1016/j.ejca.2011.08.008. - DOI - PubMed
    1. National Cancer Institute NCI Dictionary of Cancer Terms. [(accessed on 21 November 2019)]; Available online: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/791790.
    1. DeSantis C., Kramer J.L., Jemal A. The burden of rare cancers in the United States. CA A Cancer J. Clin. 2017;67:261–272. doi: 10.3322/caac.21400. - DOI - PubMed
    1. Ronicke S., Hirsch M.C., Türk E., Larionov K., Tientcheu D., Wagner A.D. Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study. Orphanet J. Rare Dis. 2019;14:69. doi: 10.1186/s13023-019-1040-6. - DOI - PMC - PubMed
    1. Gatta G., Capocaccia R., Botta L., Mallone S., De Angelis R., Ardanaz E., Comber H., Dimitrova N., Leinonen M.K., Siesling S., et al. Burden and centralised treatment in Europe of rare tumours: Results of RARECAREnet—A population-based study. Lancet Oncol. 2017;18:1022–1039. doi: 10.1016/S1470-2045(17)30445-X. - DOI - PubMed

Publication types

LinkOut - more resources